Sign In
Free Newsletter
Novo Nordisk sues Eli Lilly over GLP-1 drug ads
Novo Nordisk sued Eli Lilly, alleging misleading ads unfairly compare doses of Zepbound and Mounjaro with Wegovy and Ozempic.
Novo Nordisk to evaluate semaglutide weight loss implant
Novo Nordisk will evaluate Vivani Medical's semaglutide implant for chronic weight management under a new development agreement.
Novo Nordisk teams with OpenAI to speed drug development
Novo Nordisk and OpenAI partner to use AI for drug development, aiming to speed discovery, improve manufacturing and boost efficiency.
Novo Nordisk, Hims & Hers settle GLP-1 drug dispute
The settlement between Novo Nordisk and Hims & Hers allows the telehealth platform to sell FDA-approved Wegovy and Ozempic GLP-1 drugs.
ShopRite launches GLP-1 wellness starter kits
Customers filling their first prescription will receive product samples, nutrition guides and recipes to support patients beginning weight loss medications.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Novo Nordisk to cut 9,000 jobs in global restructuring
The moves aim to save $1.3 billion annually by next year, streamline operations and increase focus on diabetes and obesity growth.
Novo Nordisk expands Wegovy access as FDA bans semaglutide copies
The Swiss drugmaker – which has its U.S. headquarters in Plainsboro – is launching a series of initiatives to offer patients authentic versions of its blockbuster weight-loss treatment.
Frier Levitt to host webinar on GLP-1 legal risks
The boutique health care firm will host a May 15 event exploring compounding, legal risks, FDA regulations and the growing role of payers in obesity treatment.
Novo Nordisk scores court win against GLP-1 copycat compounders
A Texas court denied a request to allow continued sales of compounded Wegovy and Ozempic after the FDA ruled the semaglutide shortage has ended.
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
An industry group filed the lawsuit after the health regulator removed semaglutide from its shortage list and told manufacturers they need to stop producing unbranded versions within the next 60 to 90 days.
GLP-1 users spend less at the supermarket, Cornell study finds
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, including decreasing sales for certain kinds of foods.
